Related Experiment Video
Updated: May 13, 2026

10:26
Inducing Apical Periodontitis in Mice
Published on: August 6, 2019
Associations between CD14 -159 C>T polymorphism and chronic/aggressive periodontitis susceptibility
Oral Diseases
|March 23, 2013
Summary
The CD14 -159 C>T gene variant is linked to periodontitis development. This polymorphism is associated with a decreased risk of mild to moderate periodontitis, but not severe forms.
Area of Science:
- Genetics
- Periodontology
- Molecular Biology
Background:
- CD14 is implicated as a causative gene in periodontitis.
- Previous studies on the association between CD14 -159 C>T polymorphism and periodontitis have yielded conflicting results.
- This necessitates a comprehensive meta-analysis to clarify the relationship.
Purpose of the Study:
- To conduct a meta-analysis evaluating the association between the CD14 -159 C>T polymorphism and periodontitis susceptibility.
- To resolve conflicting findings regarding this genetic variant's role in periodontitis.
Main Methods:
- A meta-analysis was performed on eight relevant case-control studies.
- Odds ratios (OR) with 95% confidence intervals (CIs) were used to assess the association.
- Statistical heterogeneity was evaluated using the Chi-square-based Q-test.
Main Results:
- The meta-analysis included retrieved studies on CD14 -159 C>T and periodontitis.
- Overall and subgroup analyses were conducted.
- The CD14 -159 C>T polymorphism was not found to significantly alter overall periodontitis risk across ethnicities or disease types.
- However, a decreased risk of mild to moderate periodontitis was observed with this polymorphism (TT vs. CC: OR=0.42, 95% CI=0.21-0.81; CT/CC vs. TT: OR=1.91, 95% CI=1.09-3.35).
- No significant association was found for severe periodontitis.
Conclusions:
- The meta-analysis provides evidence that the CD14 -159 C>T polymorphism is involved in the pathogenesis of periodontitis.
- Specifically, it appears to influence the risk of developing mild to moderate forms of the disease.
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...